INTRODUCTION {#sec1}
============

The absolute incidence of stroke will continue to rise globally with a predicted 12 million stroke deaths in 2030 and 60 million stroke survivors worldwide ([@B14]). Stroke leads to focal lesions in the brain due to cell death following hypoxia and inflammation, affecting both gray and white matter tracts ([@B8]). After a stroke, a wide range of deficits can occur with varying onset latencies such as hemiparesis, abnormal posture, spatial hemineglect, aphasia, and spasticity, along with affective and cognitive deficits, chronic pain, and depression ([@B34]). Due to improved treatment procedures during the acute stage of stroke (e.g., thrombolysis and thrombectomy), the associated reduction in stroke mortality has led to a greater proportion of patients facing impairments and needing long-term care and rehabilitation. However, prevention, diagnostics, rehabilitation, and prognostics of stroke recovery have not kept pace ([@B35]).

Motor recovery after stroke has been widely operationalized as the individual's change in two domains: *1*) body function and structure ([@B38]), whose improvement has been called "true recovery" ([@B5]) and refers to the restitution of a movement repertoire that the individual had before the injury; and *2*) the ability to successfully perform the activities of daily living ([@B25]). While the former is mainly due to the interaction of poststroke plasticity mechanisms and sensorimotor training, the latter is also influenced by the use of explicit and implicit compensatory strategies ([@B5]; [@B22]). The most accepted measure for recovery of body function and structure is the change in the Fugl-Meyer Assessment of the upper extremity (UE-FM) scores ([@B22]), while other clinical scales focus on the assessment of activities, such as the Chedoke Arm and Hand Activity Inventory (CAHAI) ([@B3]) or the Barthel Index for Activities of Daily Living (BI) ([@B16]).

Poststroke motor recovery mostly follows a nonlinear trajectory that reaches asymptotic levels a few months after the injury ([@B21]). This model suggests the existence of a period of heightened plasticity in which the patient seems to be more responsive to treatment, the so-called "critical window" for recovery. Aiming at characterizing the temporal structure of recovery, animal models and clinical research have identified a combination of mechanisms underlying neurological repair that seems to be unique to the injured brain, including neurogenesis, gliogenesis, axonal sprouting, and the rebalancing of excitation and inhibition in cortical networks ([@B36]). This state of enhanced plasticity seems to be transient and interacts closely with sensorimotor training to facilitate the recovery of motor function ([@B39]). However, there is no clear evidence of the exact temporal structure of enhanced responsiveness to treatment in humans, and as a result the optimal timing and intensity of treatment remain unclear. A systematic review of 14 studies suggested that, on average, recovery reaches a plateau at 15 wk poststroke for patients with severe hemiparesis and at 6.5 wk for patients with mild hemiparesis ([@B17]). This study however failed to conduct a meta-analysis due to substantial heterogeneity of the sample and protocols. Currently, an ongoing clinical trial is investigating the existence and the duration of a critical window of enhanced neuroplasticity in humans following ischemic stroke ([@B28]). Based on the assumption of the existence of this critical period, the SMARTS 2 trial (NCT02292251) ([@B20]) is currently investigating the effect of early and intensive therapy on upper extremity motor recovery. Sharing the same research question, the Critical Periods After Stroke Study (CPASS) is a large ongoing randomized controlled trial that focuses on determining the optimal time after stroke for intensive motor training ([@B10]). To contribute to the delineation of a temporal structure of stroke recovery in humans, we performed an analysis of individual patient clinical data from 219 subjects with upper-limb hemiparesis, who followed occupational therapy (OT) or a virtual reality (VR)-based training protocol using the Rehabilitation Gaming System (RGS) ([@B6]) (Fig. S1 in Supplemental Material; all Supplemental material is available at <https://doi.org/10.5281/zenodo.3246368>). We show that physical therapy has a significant impact on the function of the upper extremity (UE) at all periods poststroke considered, uncovering a gradient of responsiveness to treatment that extends \>12 mo poststroke.

MATERIALS AND METHODS {#sec2}
=====================

 {#sec2-1}

### Data sets. {#sec2-1-1}

In this analysis, we included individual patient data from a set of protocols for the recovery of upper extremity function. These protocols included interventions combining OT and a specific VR training protocol (RGS) (Section 1 in Supplemental Material). Participants met the following inclusion criteria: *1*) ischemic strokes (middle cerebral artery territory) or hemorrhagic strokes (intracerebral); *2*) mild-to-moderate upper limb hemiparesis (Medical Research Council scale for proximal muscles \>2) after a first-ever stroke; *3*) age between 45 and 85 yr old; and *4*) the absence of any significant cognitive impairment (Mini-Mental State Evaluation \>22). All research on human subjects reported in this manuscript was prospectively approved by the Institutional Review Board of Hospital Joan XXIII, Hospital Vall d'Hebron and Hospital del Mar i l'Esperança from Catalonia, and all participants provided written informed consent.

The data sets were divided into 17 conditions depending on the specific characteristics of the patients and the requirements of the treatment provided ([Table 1](#T1){ref-type="table"}). Most of the RGS conditions included in this analysis have an identical design based on the same set of neurorehabilitation principles ([@B26]) (see Supplemental Material for a full description of the system and its mechanisms). However, two relevant design differences should be noticed. First, in two protocols used with acute patients the dosage was three days a week instead of five (*conditions 5* and *6* in [Table 1](#T1){ref-type="table"}). Second, in one study the implicit feedback is augmented through haptic actuators (*condition 14* in [Table 1](#T1){ref-type="table"}, RGS Haptics).

###### 

Overview of therapy conditions

  ID                        Group    Average Chronicity          Intervention          *N*   Mean Age (SD)     TSO (SD)      HA (%left)   Sex (%men)   Oxf. Class.            References
  ----------------------- --------- -------------------- ---------------------------- ----- --------------- --------------- ------------ ------------ -------------- -----------------------------
  *Acute stage*                                                                                                                                                      
  1                        Control         Acute                12w;5d/w;20min          5       69 (19)         9 (15)           40           80        2/1/0/1/1              ([@B12])
  2                          RGS           Acute                3w;5d/w;20min           5       70 (22)         11 (4)           60           20        1/2/0/1/1          ([@B12]; [@B32])
  3                          RGS           Acute                12w;3d/w;20min         10      63.5 (29)        11 (17)          40           30        2/2/2/3/1           ([@B9]; [@B12])
  4                        Control         Acute                3w;5d/w;20min           5       64 (16)         13 (5)           60           60        2/2/0/0/1          ([@B12]; [@B32])
  5                        Control         Acute             12w;3d/w;20min; NSG        4       65 (28)         13 (12)          75           50        1/0/1/1/1               ([@B9])
  6                        Control         Acute             12w;3d/w;20min; IOT        5       56 (27)         15 (11)          40           40        1/1/2/0/1               ([@B9])
  *Subacute stage*                                                                                                                                                   
  7                          RGS          Subacute              3w;5d/w;20min          49       61 (43)        70 (375)         30.6         30.6      11/9/13/1/15   (See Supplemental Material)
  8                        Control        Subacute              3w;5d/w;20min           4       57 (17)        90 (226)          0            50        4/0/0/0/0     (See Supplemental Material)
  *Early chronic stage*                                                                                                                                              
  9                          RGS          Chronic             6w;5d/w;30min; +AM        9       63 (31)       400 (5,805)       33.3         33.3                               ([@B1])
  10                         RGS          Chronic               6w;5d/w;30min           9       57 (36)       735 (4,471)       11.1         55.6                               ([@B1])
  11                       Control        Chronic         3w;5d/w;20min; domiciliary   18      68.5 (40)      751 (1,536)       33.3          50        6/2/4/0/6           ([@B2]; [@B29])
  12                         RGS          Chronic             3w;5d/w;20min; +OT       20      64.5 (37)      770 (2,789)        40           30        7/0/4/0/9              ([@B12])
  *Late chronic stage*                                                                                                                                               
  13                         RGS        Late Chronic      3w;5d/w;20min; domiciliary   17      61.5 (43)      997 (2,987)       47.1         35.3       4/3/4/0/6           ([@B2]; [@B29])
  14                         RGS        Late Chronic        4w;5d/w;30min; haptics     14       63 (45)      1,051 (3,250)       50          57.1       6/0/4/1/3               ([@B6])
  15                         RGS        Late Chronic            3w;5d/w;30min          15       58 (60)      1,261 (2,041)      33.3         46.7       0/1/2/0/12             ([@B12])
  16                         RGS        Late Chronic            4w;5d/w;30min          16      69.5 (46)     1,536 (3,891)      43.8         62.5       6/4/5/0/1               ([@B6])
  17                         RGS        Late Chronic      4w;5d/w;30min; exoskeleton   14       60 (32)      1,758 (2,880)      35.7         71.4       3/1/4/1/5               ([@B6])

Intervention: duration of included protocols indicated per number of weeks (w), days per week (d/w), and minutes (min) of occupational therapy (OT) and virtual reality (VR)-based therapy per day. AM, condition including the amplification of movements in VR; HA, percentage of patients with left hemisphere affected; Haptics, condition including delivery of haptic feedback during training; IOT, condition including intensive occupational therapy; *N*, sample size in the experimental group; NSG, protocol based on nonspecific gaming system (i.e., Nintendo Wii); Oxf. Class., count of stroke types \[lacunar stroke (LACS)/partial anterior circulation stroke (PACS)/total anterior circulation stroke (TACS)/or posterior circulation stroke (POCS)\] according to the Oxford Stroke Classification scale; RGS, Rehabilitation Gaming System; Sex, percentage of men; TSO, median (maximum − minimum) days since the stroke.

Furthermore, all RGS protocols used by acute and subacute patients combined RGS-based training with supervised OT, while *condition 13* tested the application of RGS in a domiciliary setting. Despite these differences, in all RGS conditions the same protocol was used. A formal risk of bias analysis on the primary outcome (i.e., change in the UE-FM) was performed using ROBINS-I tool (Table S1 in Supplemental Material) covering the evaluation of confounding variables, recruitment for participants, intervention classification, deviations from intended interventions, missing data, measurement of outcomes, and selection of reported results.

### Outcome measures. {#sec2-1-2}

The primary outcome considered in this analysis was the UE motor impairment and activity at the end of therapy, as measured by two standardized clinical scales: the UE-FM and CAHAI ([@B3]) scales. Previous studies have shown that the UE-FM shows excellent reliability, responsiveness, and validity properties ([@B37]). Second, the CAHAI evaluates the UE bilateral function in the performance of specific iADLs ([@B3]). Score changes in the UE-FM and CAHAI were used as measures of motor improvement (body function and structure) and performance in Instrumental Activities of Daily Living (iADLs), respectively. In addition, the BI ([@B16]) was considered a secondary outcome for the assessment of the patient's level of independence.

### Statistical analysis. {#sec2-1-3}

We performed two analyses. First, we explored recovery measures independently within each of the 17 conditions. In this analysis, we examined recovery measures using the UE-FM and CAHAI in absolute terms. Here, we quantified improvement using mean differences and 95% confidence intervals (CI). Second, we analyzed the temporal structure of recovery poststroke by merging all the conditions (178 patients performing RGS-based training and 368 follow-up measures) and bootstrapping our data using the Efron and Tib method (Efron and Tibshirani 1986) to evaluate the effects of the therapy across the patients' chronicity (subacute, early chronic, and late chronic). This method overcomes the high intersubject variability and provides a superior statistical power ([@B11]). The homogenized data were generated by separating improvement measures at different time intervals and allocating them to either being an RGS-based training, OT based-training, or follow-up (i.e., no therapy). We then calculated the improvement rate per week normalized within subjects according to their respective recovery potential. This metric therefore captures the improvement observed normalized to the total amount that each patient can gain given the baseline of each in standardized clinical scales. The normalized improvement (NI) on scale *i* at time *t* was defined as:$$NI\left( {i,t} \right) = \left\lbrack \frac{X_{i}\left( t \right) - X_{i}\left( {t = 0} \right)}{MAxScore_{i} - X_{i}\left( {t = 0} \right)} \right\rbrack \times 100$$where *X~i~* (*t* = 0) refers to the corresponding baseline score. According to this normalization method, a patient with a baseline score of 16 in UE-FM will have 50 points of potential improvement since the UE-FM has a maximum score of 66 ([@B9]). In case this patient would recover 10 points, reaching a score of 26 points in the scale at T1, this would be equal to 20% (i.e., 10/50) of NI. Note that this value may depend on the time lapsed between baseline measurement and subsequent assessments. We overcome this bias by dividing the NI by the number of weeks between both measurement time points, therefore obtaining an estimate of NI per week. This normalization method allowed us to bundle the data of the different conditions while overcoming the risk of bias due to the variation in treatment intensity and response rates among protocols ([@B24]; [@B27]; [@B33]). We computed a NI value for two time intervals: postassessment and long-term follow-up. For example, for a patient who followed RGS training with a baseline, end of the treatment, and follow-up assessment, we calculated the NI per week for two periods: baseline to end of the treatment and end of the treatment to long-term follow-up. The measured change from baseline to the end of the treatment was allocated to the RGS or the OT group, while the change from the end of the treatment to follow-up was assigned to the follow-up group. If a patient had multiple follow-up assessments at different time points, all the follow-up measures were assigned to the follow-up group.

For all tests, statistical significance levels were set at *P* \< 0.05. Average and dispersion values are reported in medians ± median absolute deviation (MAD) or means ± SD according to results from normality assessments (Kolmogorov-Smirnov normality test). To facilitate the exploration and replication of our findings, we published the complete data set and analysis source code as freely available and open, accessible at <https://doi.org/10.5281/zenodo.3246368>.

RESULTS {#sec3}
=======

 {#sec3-1}

### Impact assessment of individual conditions. {#sec3-1-1}

The complete data set includes 219 stroke survivors assigned to 17 rehabilitation conditions ([Table 1](#T1){ref-type="table"}) at different stages post-stroke: acute (\<3 wk), subacute (3 wk--6 mo), early chronic (6--18 mo), and late chronic (\>18 mo). We observed significant gains in body function and structure after treatment, both in acute (median 20.0 ± 7.9 MAD, *P* \< 0.01) and subacute patients (median 8.0 ± 5.6 MAD, *P* \< 0.01), as measured by UE-FM ([Fig. 1*A*](#F0001){ref-type="fig"}; Table S1 in Supplemental Material). These gains were accompanied by an improved performance in iADLs in both acute (median 42.5 ± 14.1 MAD, *P* \< 0.01) and subacute groups (median 7.0 ± 10.5 MAD, *P* \< 0.01) ([Fig. 1*B*](#F0001){ref-type="fig"}; Table S2 in Supplemental Material). More interestingly, at the chronic and late chronic stage, the therapy showed overall effectiveness in facilitating improvements in UE-FM (ranging from median 2.7 ± 3.8 MAD to median 7.0 ± 3.6 MAD, *P* \< 0.05) and CAHAI (median 1.0 ± 3.8 MAD to median 8.0 ± 5.6 MAD, *P* \< 0.05). The application of the RGS at home showed no significant effects in UE-FM but induced statistically significant gains in the execution of iADLs (median 1.0 ± 1.6 MAD, *P* \< 0.01). Surprisingly, a dosage-matched RGS study conducted in the clinic on late chronic patients had an impact on UE-FM (*condition 15* in [Table 1](#T1){ref-type="table"}, median 3.0 ± 4.1 MAD, *P* \< 0.01; [Fig. 1](#F0001){ref-type="fig"}, *A* and *B*, condition Late Chronic 3w). Furthermore, we observed a clear dependency between the number of days post-stroke before the start of the RGS therapy and the improvements in motor function as measured by UE-FM and CAHAI (*P* \< 0.001, Spearman correlation).

![Effect of Rehabilitation Gaming System (RGS)-based treatment from the start (baseline) to the end of the treatment (T1). Impact measured on upper limb motor function in the Upper Extremity section of the Fugl-Meyer scale (UE-FM; *top*) and performance in Instrumental Activities of Daily Living (iADLs) captured by the Chedoke Arm and Hand Activity Inventory (CAHAI; *bottom*). The effect represents a change in each scale from the start to the end of the treatment. Notice that the horizontal axis refers to the RGS conditions listed in [Table 1](#T1){ref-type="table"} and follows the same order. Shaded areas indicate the data distribution color coded according to the chronicity of stroke patients participating in each rehabilitation condition: acute (green), subacute (orange), early (blue), and late (purple) chronic stage. \**P \<* 0.05, \*\**P* \< 0.01.](z9k0071951220001){#F0001}

The analysis of follow-up measures illustrates that improvements were retained in all groups. The subacute group training with RGS exhibited a significant improvement during the follow-up period (3 mo after the end of treatment) both in UE-FM (median 2.0 ± 5.3 MAD, *P* \< 0.01) and CAHAI (median 3.0 ± 11.7 MAD, *P* \< 0.01) (Fig. S3, *A* and *B*, in Supplemental Material). The acute groups, however, showed higher interindividual variability and nonsignificant gains from the end of the therapy to the follow-up.

### Revealing an extended critical window for recovery. {#sec3-1-2}

To study the temporal structure of recovery after a stroke, we now combined the impact of all the conditions and examined the effects of chronicity on the patients' normalized improvement (NI; see *Eq. 1* in [materials]{.smallcaps} [and]{.smallcaps} [methods]{.smallcaps}). In the group receiving therapy (RGS), we observed a mean UE-FM NI per week of 5.2 ± 1.0 SD % in subacute (median 10.3 wk) and 2.7 ± 0.6 and 1.4 ± 0.3 SD % in early chronic (median 12.0 mo) and late chronic (median 3.9 yr) patients, respectively ([Fig. 2](#F0002){ref-type="fig"}, *top left*). The change on the CAHAI scale shows a mean NI per week of 3.4 ± 0.7 SD % in subacute, and 1.9 ± 0.4 and 1.1 ± 0.2 SD % in early and late chronic patients, respectively ([Fig. 2](#F0002){ref-type="fig"}, *bottom left*). We found statistically significant differences between subacute and early chronic patients, even during the follow-up period (*P* \< 0.01, Wilcoxon Rank-Sum). Those patients at the subacute phase showed higher NI per week. However, only in the RGS group, the early chronic group (6--18 mo) showed higher recovery rates than the late chronic group (\>18 mo) (*P* \< 0.05, Wilcoxon Rank-Sum). This analysis reveals a long-lasting gradient of sensitivity to treatment that remains visible across the first 18 mo post-stroke ([Fig. 2](#F0002){ref-type="fig"}, *right*). This effect was not present in the follow-up measures, a period in which no therapy was administered. Due to the low number of chronic patients in the OT group, we could not apply the bootstrapping method to this sample for comparison. Despite this, we display the full data to allow for visual inspection.

![*A*: averaged normalized improvement rates per week after the Rehabilitation Gaming System (RGS)-based treatment and at follow-up (FU) for Upper Extremity section of the Fugl-Meyer scale (UE-FM; *top*) and Chedoke Arm and Hand Activity Inventory (CAHAI) scales (*bottom*) by patient's chronicity at the time of the evaluation. The number of observations is indicated within or above each bar. \**P* \< 0.05, \*\**P* \< 0.01. *B*: comparison of the RGS, occupational therapy (OT), and FU measures of normalized improvement rates per week for UE-FM (*top*) and CAHAI (*bottom*) scales, by patient's chronicity at the time of the evaluation. Solid lines indicate the average estimates based on the Whittaker smoothing algorithm ([@B14]). Vertical dashed lines indicate the limits of the 3 chronicity categories.](z9k0071951220002){#F0002}

The patient's age could not explain the gradient of sensitivity to treatment found in the RGS group even at early and late chronic stages (Spearman's correlation *r* \< 0.003, *P* \> 0.96) and neither by the patient's baseline impairment score (Spearman's correlation *r* \< 0.052, *P* \> 0.43 for FM; *r* \< 0.006, *P* \> 0.93 for CAHAI). Notice that the design of this analysis controls for additional confounding variables since all patients were recruited according to standard inclusion and exclusion criteria concerning age, motor impairment severity, cognitive impairment severity, type of stroke (Oxford Classification), hand dominance, the absence of a second stroke, and gender. None of these variables correlate with the patients' chronicity, and therefore none of them can explain the uncovered gradient. The homogeneity of the demographics of these patients in combination with highly heterogeneous chronicity highlights the peculiarity of this data sample.

Finally, we analyzed the covariation of the recovery measures of the different clinical scales. We observed a distinct effect of the patient's chronicity on the association of ∆UE-FM, ∆CAHAI, and ∆BI scores. While at the acute/subacute stages these recovery measures correlate, they do progressively dissociate as the patient advances toward the late chronic stage ([Fig. 3](#F0003){ref-type="fig"}).

![Spearman correlation coefficients of recovery scores captured by the Upper Extremity section of the Fugl-Meyer scale (UE-FM), Chedoke Arm and Hand Activity Inventory (CAHAI), and Barthel Index (BI), for each chronicity quartile. Q1 (2--39 days), Q2 (39--430 days), Q3 (439--1,198 days), and Q4 (1,198--5,844 days). Dashed horizontal lines indicate significance thresholds.](z9k0071951220003){#F0003}

DISCUSSION {#sec4}
==========

In opposition to compensation, recovery of body function and structure ([@B25]) \[i.e., "true recovery" according to ([@B5])\] refers to the partial or complete restoration of the repertoire of behaviors that was available before injury ([@B5]; [@B40]). In the absence of a precise assessment of kinematic and kinetic measures, recovery of body function and structure has been operationalized as the change in UE-FM scores ([@B5]). Previous studies on humans have identified a 3- to 6-mo period of enhanced neuroplasticity mechanisms triggered by the injury ([@B17]; [@B19]). Here, by analyzing clinical recovery scores from stroke patients with variable chronicity but comparable baseline impairment levels, we are able to detect a smooth decrease in the sensitivity to treatment (i.e., critical window for recovery) that extends beyond 12 mo post-stroke. These results suggest that there is a long-lasting critical period of enhanced neuroplasticity post-stroke that enables improvement in body function and structure even at late chronic stages. This is the first time that such an extended critical period of recovery is reported. Capturing this effect may require large homogeneous data sets and analytic methods with enhanced accuracy such as the bootstrapping technique we apply here.

In line with the previous literature, our data illustrate the correlation of ∆UE-FM with ∆CAHAI and ∆BI scores at acute stages ([@B4]; [@B31]). However, we found that at chronic stages these scales dissociate, possibly due to the introduction of compensatory mechanisms ([@B31]). Altogether, our data support the interpretation of UE-FM as an assessment of recovery of body function and structure that is independent of improvement in the performance of iADLs and closely associated with true neurological repair ([@B21]).

The results presented in this study do require further investigation for a number of reasons. The clinical importance of the detected improvements is marginal at late chronic stages. It is relevant to notice, however, that the UE-FM minimal clinically important difference (MCID) is derived from the chronicity-dependent variability in the UE-FM's measurement error and the patient's perceived improvement thresholds ([@B30]). According to previous studies, the UE-FM MCID ranges from 16 to 30% of the scale's maximum value at acute stages (\<30 days post-stroke) ([@B23]), and from 7.2 to 11.0% at chronic stages (\>4 mo post-stroke) ([@B30]). In the case of CAHAI, MCID thresholds have been established above 7% of the scale range (6.3 points) for "stable patients" within the first year post-stroke ([@B3]). If the reduction of the sensitivity to treatment revealed by our analysis exists and extends beyond 12 mo post-stroke, these MCID estimates could be better described as a continuous function of chronicity and should differentiate between late chronic and early chronic patients. Future studies should explore this relationship to delineate more accurate MCID thresholds.

It is important to note that the uncovered gradient of sensitivity to therapy may not be specific to VR-based interventions. However, due to the low number of chronic patients in the OT group, we could not perform a bootstrapping analysis in this sample, and we were thus not able to evaluate the limits of the critical window in these patients. Therefore, the generalization of our findings to therapies based on different rehabilitation methods (e.g., Constraint-Induced Movement Therapy) needs to be investigated. The factors determining the duration of this critical window and the decay rate of the patient's responsiveness to treatment deserve further investigation.

Our results suggest that, as during ontogenesis, the reacquisition of function after stroke might have to be seen as a process that must satisfy distinct dependencies. Multiple sensitive periods for the acquisition of motor and cognitive function may be structured according to specific dependencies. For instance, in postnatal stages, the development of neural pathways for sensory processing precedes those of language and motor functioning ([@B18]). Based on our results, we speculate that the temporal structure of recovery post-stroke may also comprise such a cascade of domain-specific stages or critical periods. Clinical protocols for rehabilitation should be evaluated in this new context.

 {#sec4-1}

### Conclusion. {#sec4-1-1}

We have investigated the distinct dynamics of post-stroke recovery and the sensitivity to treatment. By unifying results from 11 rehabilitation pilot studies, we observed improvement in function over at all stages post-stroke. This effect displayed a specific gradient of recovery that faded out exponentially and reached asymptotic levels after one year and a half post-stroke. These findings call for an urgent scientific effort to reassess the critical window for recovery and highlight the need for both providing early therapy and extending it to patients in the chronic stages post-stroke.
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